Cargando…

Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis

INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) comprises a wide range of related liver disorders affecting mainly people who drink no or very little alcohol. Aramchol is a new synthetic molecule that has been shown to reduce liver fat content. There is little evidence supporting its efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malik, Adnan, Nadeem, Mahum, Amjad, Waseem, Malik, Muhammad Imran, Javaid, Sadia, Farooq, Umer, Naseem, Khadija, Khan, Ahmad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050975/ https://www.ncbi.nlm.nih.gov/pubmed/37007760 http://dx.doi.org/10.5114/pg.2022.113573

Ejemplares similares

The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials
por: Malik, Adnan, et al.
Publicado: (2022)

Efficacy of endoscopic trans-papillary gallbladder stenting and drainage in acute calculous cholecystitis in high-risk patients: a systematic review and meta-analysis
por: Malik, Adnan, et al.
Publicado: (2023)

Role of aramchol in steatohepatitis and fibrosis in mice
por: Iruarrizaga‐Lejarreta, Marta, et al.
Publicado: (2017)

Evaluation of the effect of probiotics on septic complications in patients with severe acute pancreatitis. A systematic review and meta-analysis
por: Malik, Adnan, et al.
Publicado: (2022)

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
por: Carulli, Lucia, et al.
Publicado: (2019)

Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Del Campo, José A, et al.
Publicado: (2018)

Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
por: Zarghamravanbakhsh, Paria, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
por: Dorairaj, Vicneswarry, et al.
Publicado: (2021)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review
por: Sulaiman, Siti Aishah, et al.
Publicado: (2022)

Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Conlon, Beth A., et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
por: Singh, Shivaram P., et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
por: Di Ciaula, Agostino, et al.
Publicado: (2021)

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
por: Fang, Tingyu, et al.
Publicado: (2022)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis
por: Bhattacharya, Dipankar, et al.
Publicado: (2021)

Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD)
por: Chen, Qian, et al.
Publicado: (2017)

Sex Dimorphism of Nonalcoholic Fatty Liver Disease (NAFLD) in Pparg-Null Mice
por: Schiffrin, Mariano, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
por: Pafili, Kalliopi, et al.
Publicado: (2020)

Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
por: Bernstein, David, et al.
Publicado: (2022)

Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
por: Polyzos, Stergios A., et al.
Publicado: (2020)

Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma
por: Enooku, Kenichiro, et al.
Publicado: (2019)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
por: Ortiz-Lopez, Carolina, et al.
Publicado: (2012)

Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)
por: Raszeja-Wyszomirska, Joanna, et al.
Publicado: (2010)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
por: Portillo-Sanchez, Paola, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
por: Jamwal, Rohitash, et al.
Publicado: (2020)

PIN1, a perspective on genetic biomarker for nonalcoholic fatty liver disease (NAFLD)
por: Wang, Jing-Zhang, et al.
Publicado: (2019)

Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
por: Nasiri-Ansari, Narjes, et al.
Publicado: (2022)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis
por: Rasool, Abid, et al.
Publicado: (2017)

Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges
por: Ahmad, Muhammad Imran, et al.
Publicado: (2022)

Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
por: Tapper, Elliot B., et al.
Publicado: (2016)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
por: Wen, Xuerong, et al.
Publicado: (2021)

Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
por: Yoneda, Masato, et al.
Publicado: (2008)

Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease
por: Mirza, M. S.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_leduql820q8ucfjqmq7upuppob